Cart
sales@molnova.com
Litifilimab
CAS No. 2407378-48-5
Litifilimab( —— )
Catalog No. M37172 CAS No. 2407378-48-5
Litifilimab, a humanized IgG1-κ antibody, targets the C-type lectin domain family 4 member C (CLEC4C) and has potential applications in the study of cutaneous lupus erythematosus (CLE) .
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameLitifilimab
-
NoteResearch use only, not for human use.
-
Brief DescriptionLitifilimab, a humanized IgG1-κ antibody, targets the C-type lectin domain family 4 member C (CLEC4C) and has potential applications in the study of cutaneous lupus erythematosus (CLE) .
-
DescriptionLitifilimab is a humanized IgG1-κ antibody targeting to C-type lectin domain family 4 member C (CLEC4C). Litifilimab can be used for cutaneous lupus erythematosus (CLE) study.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2407378-48-5
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Cho SK, et al. Litifilimab (BIIB059), a promising investigational drug for cutaneous lupus erythematosus. Expert Opin Investig Drugs. 2023 May;32(5):345-353.?
molnova catalog
related products
-
alpha-Asarone
Alpha-Asarone is a psychoactive compound with antidepressant-like activity in mice.
-
PF-03382792
PF-03382792 (PF-3382792) is a clinical compound under phase 1 investigation for an unknown indication.
-
SHMT-IN-2
SHMT-IN-2 (compound 2) is a specific human SHMT1/2 small molecule inhibitor that acts on SHMT1 (IC50: 13 nM) and SHMT2 (IC50: 66 nM). SHMT-IN-2 inhibits the growth of many human cancer cells and is sensitive to B-cell lymphoma.
